Use of tavapadon in treating parkinson's disease

A method for treating Parkinson's Disease in a patient, wherein the method comprises:

• a titration phase comprising orally administering to the patient:
• 0.25 mg per day dose of tavapadon for days 1-4 of the titration phase;
• 0.5 mg per day dose of tavapadon for days 5-8 of the titration phase;
• 0.75 mg per day dose of tavapadon for days 9-12 of the titration phase;
• 1.0 mg per day dose of tavapadon for days 13-16 of the titration phase;
• 1.5 mg per day dose of tavapadon for days 17-20 of the titration phase;
• 2.25 mg per day dose of tavapadon for days 21-24 of the titration phase;
• 3 mg per day dose of tavapadon for days 25-40 of the titration phase;
• and
• a therapeutically effective amount of 5 mg per day dose of tavapadon for days 41-56 of the titration phase;
• thereby treating the Parkinson's Disease.

A method for treating Parkinson's Disease in a patient, wherein the method comprises:

• i. a titration phase comprising orally administering to the patient:
• 0.25 mg per day dose of tavapadon for days 1-4 of the titration phase;
• 0.5 mg per day dose of tavapadon for days 5-8 of the titration phase;
• 0.75 mg per day dose of tavapadon for days 9-12 of the titration phase;
• 1.0 mg per day dose of tavapadon for days 13-16 of the titration phase;
• 1.5 mg per day dose of tavapadon for days 17-20 of the titration phase;
• 2.25 mg per day dose of tavapadon for days 21-24 of the titration phase;
• 3 mg per day dose of tavapadon for days 25-40 of the titration phase;
• and a therapeutically effective amount of 5 mg per day dose of tavapadon for days 41-56 of the titration phase;
• ii. followed by an adjustment phase comprising orally administering to the patient:
• a therapeutically effective amount of 10 mg per day dose of tavapadon, and
• a therapeutically effective amount of 15 mg per day dose of tavapadon,
• wherein the dose of tavapadon is adjusted over the range of 5, 10 or 15 mg based on patient tolerability;
• and
• iii. followed by a maintenance phase comprising orally administering to the patient:
• a therapeutically effective amount of 5, 10 or 15 mg per day dose of tavapadon;
• wherein the patient is administered the highest tolerated dose achieved during the adjustment phase and the maintenance phase maintains the patient on a steady dose of tavapadon,
• thereby treating the Parkinson's Disease.

A method for treating Parkinson's Disease in a patient, wherein the method comprises:

• i. a titration phase comprising orally administering to the patient:
• 0.25 mg per day dose of tavapadon for days 1-4 of the titration phase;
• 0.5 mg per day dose of tavapadon for days 5-8 of the titration phase;
• 0.75 mg per day dose of tavapadon for days 9-12 of the titration phase;
• 1.0 mg per day dose of tavapadon for days 13-16 of the titration phase;
• 1.5 mg per day dose of tavapadon for days 17-20 of the titration phase;
• 2.25 mg per day dose of tavapadon for days 21-24 of the titration phase;
• 3 mg per day dose of tavapadon for days 25-40 of the titration phase;
• and a therapeutically effective amount of 5 mg per day dose of tavapadon for days 41-56 of the titration phase;
• ii. followed by an adjustment phase comprising orally administering to the patient:
• a therapeutically effective amount of 10 mg per day dose of tavapadon, and
• wherein a patient who is unable to increase the dose from 5 mg to 10 mg on the first day of step 9 due to tolerability issues will begin a maintenance phase at the patient's maximum tolerated dose of 5 mg per day;
• and
• iii. followed by a maintenance phase comprising orally administering to the patient:
• a therapeutically effective amount of 5, 10 or 15 mg per day dose of tavapadon;
• wherein the patient is administered the highest tolerated dose achieved during the adjustment phase and the maintenance phase maintains the patient on a steady dose of tavapadon,
• thereby treating the Parkinson's Disease.